Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.

@article{Earnshaw2009CosteffectivenessOF,
  title={Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.},
  author={Stephanie R. Earnshaw and Michele R. Wilson and Anand A. Dalal and Mike G. Chambers and Priti M Jhingran and Richard Hiraiwa Stanford and Douglas W. Mapel},
  journal={Respiratory medicine},
  year={2009},
  volume={103 1},
  pages={12-21}
}
OBJECTIVE We examine the lifetime cost-effectiveness of treatment with fluticasone propionate/salmeterol (500/50 microg) compared with no maintenance treatment in COPD in the US. METHODS A decision-analytic model was developed to estimate lifetime costs and outcomes associated with fluticasone propionate/salmeterol 500/50 microg treatment, salmeterol 50 microg, and fluticasone propionate 500 microg compared to no maintenance treatment in treating COPD from a third-party US payer perspective… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

of Labor: Bureau of Labor Statistics

  • U. S. Departmen
  • Consumer price index e all urban consumers…
  • 2006
Highly Influential
4 Excerpts

Longacting b2-agonists (LABA) plus corticosteroids versus LABA alone for chronic obstructive pulmonary disease

  • I Mayers, P Jacobs, DD Marciniuk, A Chuck, J. Varney
  • [Technology report no. 83]. Ottawa: Canadian…
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…